131 related articles for article (PubMed ID: 10646909)
1. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Lage H; Helmbach H; Dietel M; Schadendorf D
Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
[TBL] [Abstract][Full Text] [Related]
2. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
3. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
4. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
5. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
6. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K
Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130
[TBL] [Abstract][Full Text] [Related]
7. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
8. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
Lage H; Dietel M
J Cancer Res Clin Oncol; 2002 Jul; 128(7):349-57. PubMed ID: 12136248
[TBL] [Abstract][Full Text] [Related]
9. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
10. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
11. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
13. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
14. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
Zhou R; Vitols S; Gruber A; Liliemark J; Wang Y; Liliemark E
Br J Haematol; 1999 May; 105(2):420-7. PubMed ID: 10233413
[TBL] [Abstract][Full Text] [Related]
15. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
17. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
Luo C; Johnston PJ; MacPhail SH; Banáth JP; Oloumi A; Olive PL
Exp Cell Res; 1998 Sep; 243(2):282-9. PubMed ID: 9743588
[TBL] [Abstract][Full Text] [Related]
18. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Kim D; Lee IS; Jung JH; Lee CO; Choi SU
Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358
[TBL] [Abstract][Full Text] [Related]
19. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II.
Yun J; Tomida A; Nagata K; Tsuruo T
Oncol Res; 1995; 7(12):583-90. PubMed ID: 8704275
[TBL] [Abstract][Full Text] [Related]
20. Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II.
Mirski SE; Gerlach JH; Cole SP
Exp Cell Res; 1999 Sep; 251(2):329-39. PubMed ID: 10471318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
